Nine (23.27%) patients were diagnosed with Philadelphia chromosome (Ph)-positive ALL, 28 (84.85%) relapsed before ssCART-19 cell treatment, 1 (3.03%) had a TP53 gene mutation, and 11 (33.33%) were evaluated as poor cytogenetic risk patients. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.